welcome to oneGRAVESvoice
- a positively charged Graves' disease and thyroid eye disease community.- join today!
- log in
Total Thyroidectomy as a Method of Choice in the Treatment of Graves’ Disease – Analysis of 1432 Patients
source: BMC Surgery
year: 2015
authors: Bojic T, Paunovic I, Diklic A, Zivaljevic V, Zoric G, Kalezic N, Sabljak V, Slijepcevic N, Tausanovic K, Djordjevic N, Budjevac D, Djordjevic L, Karanikolic A
summary/abstract:Background:
Graves’ disease represents an autoimmune disease of the thyroid gland where surgery has an important role in its treatment. The aim of our paper was to analyze the results of surgical treatment, the frequency of microcarcinoma and carcinoma, as well as to compare surgical complications in relation to the various types of operations performed for Graves’ disease.
Methods:
We analysed 1432 patients (221 male and 1211 female) who underwent surgery for Graves’ disease at the Centre for Endocrine Surgery in Belgrade during 15 years (1996-2010). Average age was 34.8 years. Frequency of surgical complications within the groups was analyzed with nonparametric Fisher’s test.
Results:
Total thyroidectomy (TT) was performed in 974 (68%) patients, and Dunhill operation (D) in 221 (15.4). Carcinoma of thyroid gland was found in 146 patients (10.2%), of which 129 (9%) were a microcarcinoma. Complication rates were higher in the TT group, where there were 31 (3.2%) patients with permanent hypoparathyroidism, 9 (0.9%) patients with unilateral recurrent nerve paralysis and 10 (1.0%) patients with postoperative bleeding. Combined complications, such as permanent hypoparathyroidism with bleeding were more common in the D group where there were 2 patients (0,9%), while unilateral recurrent nerve paralysis with bleeding was more common in the TT group where there were 3 cases (0,3%).
Conclusions:
Frequency of complications were not significantly statistically different in relation to the type of surgical procedure. Total thyroidectomy represents a safe and efficient method for treating patients with Graves’ disease, and it is not followed by a greater frequency of complications in relation to less extensive procedures.
DOI: 10.1186/s12893-015-0023-3
full text source
rareRelated
-
TEPEZZA Has Resumed Production – FAQHorizon Therapeutics, the developer of T...
-
25th International Thyroid Cancer Survivors’ ConferencePlease join us for the 25th Internationa...
-
Teprotumumab Significantly Improves Proptosis in Thyroid eye DiseasePatients with thyroid eye disease treate...
-
A Walk Through Autoimmunityhttps://www.youtube.com/watch?v=yZ6wWuAQ...
-
Prospectively Recorded and MedDRA-Coded Safety Data of Intravenous Methylprednisolone Therapy in Graves’ Orbit...Context: Safety of intravenous (IV) ste...
-
Graves’ DiseaseGraves’ disease is an autoimmune disor...
-
Treating Graves’ – Different StrokesOnce the diagnosis of hyperthyroidism du...